PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 51.83

Change

0.00 (0.00)%

Market Cap

USD 2.56B

Volume

0.59M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 49.24B
ALGN Align Technology Inc

N/A

USD 20.45B
SWAV Shockwave Medical Inc

N/A

USD 12.34B
BRKR Bruker Corporation

N/A

USD 11.77B
PODD Insulet Corporation

N/A

USD 11.64B
MASI Masimo Corporation

N/A

USD 7.20B
IRTC iRhythm Technologies Inc

N/A

USD 3.48B
AXNX Axonics Modulation Technologie..

N/A

USD 3.44B
TMDX TransMedics Group Inc

N/A

USD 3.02B
LIVN LivaNova PLC

N/A

USD 3.00B

ETFs Containing PRCT

WELP:LSE HAN-GINS Indxx Healthcare.. 1.53 % 0.00 %

N/A

USD 0.02B
WELL:LSE Hanetf Icav - Han-Gins He.. 1.52 % 0.00 %

N/A

USD 0.02B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.35 % 0.00 %

N/A

USD 0.02B
FYC First Trust Small Cap Gro.. 0.00 % 0.70 %

N/A

USD 0.26B
FYX First Trust Small Cap Cor.. 0.00 % 0.63 %

N/A

USD 0.85B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.67% 85% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.67% 85% B 85% B
Trailing 12 Months  
Capital Gain 70.55% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.55% 91% A- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.32% 60% D- 67% D+
Dividend Return 8.32% 60% D- 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.35% 90% A- 62% D
Risk Adjusted Return 28.36% 79% B- 64% D
Market Capitalization 2.56B 90% A- 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector